<DOC>
	<DOCNO>NCT01284868</DOCNO>
	<brief_summary>To explore drive heart-rate increase dose mirabegron . Subjects give beta-blocker time mirabegron .</brief_summary>
	<brief_title>A Study Healthy Young Men Look What Drives Cardiovascular Effects After Dosing With Mirabegron .</brief_title>
	<detailed_description>Impedance cardiography parameter assess compare mirabegron ( placebo ) , take combination selective beta-blocker , non-selective beta-blocker placebo .</detailed_description>
	<mesh_term>Mirabegron</mesh_term>
	<mesh_term>Propranolol</mesh_term>
	<mesh_term>Bisoprolol</mesh_term>
	<criteria>Body Mass Index 20.0 28.5 kg/m2 , inclusive Subject genotyped extensive metabolizer CYP2D6 Subject agree sexual abstinence and/or use highly effective method birth control screen 3 month last dose study medication . Examples effective method : subject 's sexual partner surgically sterilize ( least 3 month prior screen ) , subject/subject 's sexual partner use standard oral contraception practice two ( 2 ) follow contraceptive method : diaphragm spermicide intrauterine device condom combination spermicidal cream Known suspect hypersensitivity mirabegron , propranolol bisoprolol , component formulation use Any liver function test ( i.e . ALT , AST ) upper limit normal repeated measure Any clinically significant history bronchospasm , asthma , eczema , allergic rhinitis pollen season , allergic condition previous severe hypersensitivity drug ( exclude nonactive hay fever ) Any clinically significant history sinus bradycardia , first second degree atrioventricular block , metabolic acidosis , Raynaud 's disease , cardiogenic shock , right ventricular failure secondary pulmonary hypertension , bronchospasm , angina , peripheral arterial occlusive disease , overt cardiac failure , congestive heart failure , sick sinus syndrome cardiovascular ECG abnormalities Any clinically significant history disease disorder gastrointestinal , cardiovascular , respiratory , renal , hepatic , neurological , dermatological , psychiatric metabolic judge medical investigator Any clinically significant abnormality follow investigator 's review prestudy physical examination , ECG clinical laboratory test Abnormal heart rate and/or blood pressure measurement prestudy visit follow : Heart rate &lt; 50 &gt; 90 bpm ; mean systolic blood pressure &lt; 90 &gt; 140 mmHg ; mean diastolic blood pressure &lt; 40 &gt; 90 mmHg ( blood pressure measurement take triplicate subject rest supine position 5 minute ; heart rate measure automatically ) A marked baseline prolongation QT/QTc interval repeat measurement &gt; 430 m , history unexplained syncope , cardiac arrest , unexplained cardiac arrhythmia torsades de pointes , structural heart disease , family history Long QT Syndrome PR interval &gt; 200 m &lt; 120 ms Evidence second thirddegree atrioventricular block Electrocardiographic evidence complete leave bundle branch block ( LBBB ) , right bundle branch block incomplete LBBB Intraventricular conduction delay QRS duration &gt; 120 ms Pathological Qwaves ( define Qwave &gt; 40 m depth great 0.4 0.5 mV ) Evidence ventricular preexcitation Use prescribe OTC drug ( include vitamin , natural herbal remedy , e.g . St. John 's Wort ) 2 week prior admission Clinical Unit , except occasional use paracetamol ( 3 g/day ) Regular use inducer liver metabolism ( e.g . barbiturate , rifampin ) 3 month prior admission Clinical Unit Any use drug abuse within 3 month prior admission Clinical Unit History smoke 10 cigarette ( equivalent amount tobacco ) per day within 3 month prior admission Clinical Unit History drink 21 unit alcohol per week ( 1 unit = 200 ml beer 25 ml spirit 75 ml wine ) within 3 month prior admission Clinical Unit Donation blood blood product within 3 month prior admission Clinical Unit Positive serology test HBsAg , anti HAV ( IgM ) , antiHCV antiHIV 1+2 Subjects , opinion investigator , likely complete trial reason Participation clinical study within 3 month participation 3 clinical study within 12 month , prior expect date enrolment study , provide clinical study entail biological compound long terminal half life Any clinical condition , , opinion investigator would allow safe completion study</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Mechanisms Pharmacological Action</keyword>
	<keyword>Pharmacodynamics</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>